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Aims: To compare bladder cancer incidence between patients initiating pioglitazone treatment
and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or
sulfonylureas.
Methods: We identified Medicare beneficiaries aged >65 years who initiated treatment with
pioglitazone (N = 38 700), DPP-4s (N = 82 552) or sulfonylureas (N = 126 104) between 2007
and 2014 after at least 6 months without prescriptions for these drug classes. Patients were
followed from second prescription until bladder cancer outcome (2 claims within 60 days) using
a 6-month induction/latency period, censoring for treatment change, death or end of 2014.
We used propensity score-weighted Cox proportional-hazards models to obtain adjusted haz-
ard ratios (aHR) and their 95% confidence intervals.
Results: Overall mean age of participants was 75 years and 41% were men. Over a median of
1.2 treatment years, 727 beneficiaries developed bladder cancer. Pioglitazone initiators had an
increased incidence of bladder cancer (308 vs 204 [DPP-4s] or 231 [sulfonylureas] per
100 000 person-years; aHR, 1.57 [1.23-2.00] vs DPP-4s and 1.32 [1.02-1.70] vs sulfonylureas).
The increased risk emerged within the first 2 years of treatment (aHR, 1.63 [1.22-2.17] vs
DPP-4s and 1.32 [0.98-1.78] vs sulfonylureas). If treatment was discontinued within the first
2 years, the risk after 2 years post initiation was attenuated (aHR, 0.89 [0.61-1.28]) compared
with patients treated for more than 2 years (aHR, 1.45 [0.93-2.26]) both vs DPP-4s. Findings
were consistent across secondary and sensitivity analyses.
Conclusions: Pioglitazone was associated with an elevated risk of bladder cancer compared
with DPP-4s and sulfonylureas. The elevated risk emerged within the first 2 years of treatment
and was attenuated after discontinuing. Pioglitazone’s relative effectiveness should be weighed
against a small absolute increase in risk of bladder cancer.
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1 | INTRODUCTION
The safety of pioglitazone has been greatly debated in the literature
over the past decade. Before its approval by the Food and Drug
Administration (FDA) in 1999, excess bladder tumours were reported
in preclinical rat studies.1 This was thought to be a rat-specific
phenomenon2 until the 3-year PROspective pioglitAzone Clinical Trial
In macroVascular Events (PROactive) published results that revealed
excess bladder tumours in humans who were assigned pioglitazone
vs placebo (0.5%[N = 14] vs 0.2%[N = 6], respectively) in 20053;
thus, it behooved the FDA to request a 10-year safety study. When
interim results of the 10-year study revealed an increased risk of
bladder cancer after 2 years (adjusted hazard ratio (aHR), 1.44 [1.03-
2.02]),4 the FDA issued a bladder cancer warning for pioglitazone
exposure in excess of 2 years in 2011,5 a warning that was recently
re-issued in December 2016.6
Multiple publications that reported no evidence of an increased
risk of bladder cancer for pioglitazone followed the initial safety
warning,4,7–14 including the final results of the 10-year study (aHR,
1.06 [0.89-1.26])4 and a PROactive follow-up study that observed
patients for an additional period of 10 years after the trial (risk ratio
(RR), 1.05 [0.61-1.79]).12 Far fewer publications reported an
increased risk overall,15–18 including 3 more recent studies that com-
pared pioglitazone users to non-users of pioglitazone’s thiazolidine-
diones drug class at the time of pioglitazone initiation (aHR, 1.63
[1.22-2.19]),16 to those who never used pioglitazone (RR, 1.83 [1.10-
3.05]),18 and to those who received placebo (0.6% [n = 12] vs 0.4%
[n = 8]) in the Insulin Resistance Intervention after Stroke (IRIS)
trial.17
Although much has been published on the safety of pioglitazone,
explanations for discrepancies in the observed risk of bladder cancer
are not satisfactory, rendering the totality of evidence inconclusive.19
One potential explanation highlighted in this paper is comparator
choice. Others include differing data sources, whether or not preva-
lent users were included, and definition of the risk window. This is
the first study to employ the incident user design and a wide range
of secondary and sensitivity analyses in a national sample of older US
adults to compare the risk of incident bladder cancer among initiators
of pioglitazone to that among initiators of clinically meaningful alter-
natives, dipeptidyl-peptidase-4 inhibitors (DPP-4s) and sulfonylureas,
as is recommended for comparative effectiveness research to present
the least biased comparison.20,21
2 | MATERIALS AND METHODS
2.1 | Data source
We used a 20% random sample of all Medicare beneficiaries with
concurrent fee-for-service enrollment in Parts A (inpatient), B (outpa-
tient) and D (pharmacy) during at least 1 month between January
2007 and December 2014. Medicare provides public insurance to
over 98% of older US adults, and has information about demographic
and enrollment characteristics, diagnoses, procedures and dispensed
prescriptions for enrollees.22
2.2 | Study population
We included patients aged 66 years or older who had initiated treat-
ment with pioglitazone or an active comparator (DPP-4s [largely sita-
gliptin and saxagliptin] and sulfonylureas [largely glyburide, glipizide
and glimepiride]) with continuous enrollment in Medicare Parts A and
B during the year prior to drug initiation (Figure S1, Appendix S1).
Incident use required patients to have no prescription claims for the
drug classes included in each comparison during the 180-day period
prior to the initial claim and to have a second claim for the same drug
class within 90 days. The second claim date defined the cohort entry
date. Patients who initiated both pioglitazone and the comparator on
the same day were excluded because of the inability to differentiate
the individual effects of either drug. Patients with a diagnostic claim
for bladder cancer or a procedure code for common bladder cancer
treatment (bacillus Calmette-Guérin [BCG] immunotherapy, transure-
thral resection of bladder tumour [TURBT], chemotherapeutic bladder
instillation or cystectomy) at any time prior to the cohort entry date
were excluded. Because secondary malignancies account for only
1.5% of all bladder tumours,23 we did not exclude patients with a his-
tory of non-bladder malignancies, to maximize power for this rare
outcome. Treatment classification for each comparison was deter-
mined based on first qualifying treatment per patient during the study
period.
2.3 | Outcome
Incident events were defined as at least 2 International Classification
of Disease (ICD-9) diagnostic claims for bladder cancer within
60 days, an algorithm previously validated for other solid tumours.24
We included non-invasive (233.7) in addition to invasive (188.x)
claims as the majority of bladder cancers are diagnosed at an early
stage.25 The first claim date defined the event date, assuming this to
be closest to the date of actual diagnosis.
2.4 | Follow-up
The primary approach for defining the follow-up period for outcome
ascertainment, referred to here as the “as-treated” (AT) approach,
started on the cohort entry date and continued until the first occur-
rence of incident bladder cancer, disenrollment, study end (December
2014) or treatment discontinuation (no subsequent dispensing of
initiated drug class within days-supply plus a 90-day grace period).
We added an additional 6-month latent period after treatment dis-
continuation to allow time for disease manifestation and detection.
Additional analyses, referred to here as the “initial-treatment”
(IT) approach, did not censor for treatment discontinuation, similar to
the intent-to-treat model used in randomized controlled trials. We
present AT as the primary approach as non-adherence in IT analyses
can attenuate results towards the null, potentially masking drug
effects on safety outcomes. The first 6 months of follow-up were
excluded, regardless of censoring approach, to allow for time
between exposure and development of disease (induction period) to
reduce the potential for spurious associations attributable to
increased medicalization after initiation of a therapy or the possibility
of preclinical symptoms of bladder cancer influencing treatment
choice (protopathic bias). Latency and induction periods were also
varied from 0 to 12 and 0 to 18 months, respectively (Table S1,
Appendix S1).
Because the original FDA warning was for exposure in excess of
2 years, follow-up was analysed overall and was stratified at 2 years.
We further evaluated the risk of bladder cancer during the time
period in excess of 2 years after drug initiation when actual treat-
ment duration was less than 2 years. Only a subset of patients not
otherwise censored within 2 years were included in analyses evaluat-
ing associations 2 years after drug initiation.
2.5 | Detection procedures
Urologic screening and diagnostic procedures (cytology, dipstick uri-
nalysis, non-dipstick urinalysis, urine function test and cystoscopy)
were enumerated at 0 to 6 and 6 to 12 months pre- and post-drug
initiation to evaluate whether an increased incidence of bladder can-
cer could be attributed to earlier and more frequent detection result-
ing from an increased rate of urologic procedures.
2.6 | Confounding control and statistical analysis
Medicare claims A and B (medical) were available as of January 2006
but Medicare claims D (pharmaceutical) were only available as of Jan-
uary 2007. Therefore, the baseline covariate assessment period prior
to drug initiation was 6 months for medications and 12 months for
comorbidities and healthcare utilization, thus maximizing use of avail-
able data. Descriptive statistics summarized covariates. The incidence
rates of crude bladder cancer (first event per patient) were calculated
based on the Poisson distribution overall and for each treatment cat-
egory. We used propensity scores (PS) based on all covariates to con-
trol for remaining differences between the compared cohorts. The
propensities of initiating pioglitazone vs DPP-4s and pioglitazone vs
sulfonylureas were estimated for each patient using 2 separate logis-
tic regression models (1 for each comparison).26 Standardized morbid-
ity ratio (SMR) weighting that assigned the pioglitazone group a
weight of 1 and each comparator group a weight of [PS/(1-PS)]27
was used to standardize the DPP-4s and sulfonylureas comparator
covariates to the covariate distribution observed in the pioglitazone
group. We report weighted comparison columns that represent
pseudo-populations of patients initiating DPP-4s and sulfonylureas
with covariate distribution balanced to that of the pioglitazone treat-
ment group, allowing for unconfounded treatment effect esti-
mates.27,28 We used weighted Kaplan–Meier plots to evaluate the
proportional hazards assumption. Weighted Cox proportional hazards
models, with treatment as the only independent variable, were used
to estimate adjusted hazard ratios (aHRs) and 95% confidence inter-
vals (CIs) of the incidence of bladder cancer for each comparison, and
then for each detection procedure during each time period.
2.7 | Sensitivity analyses
We conducted multiple sensitivity analyses to quantify the robustness
of results. First, we assessed robustness of the outcome definition using
a more conservative (any claim) (Table S3, Appendix S1) and a more
stringent definition (requirement of additional procedure claim for blad-
der cancer treatment within 3 months of initial diagnosis) (Table S4,
Appendix S1) to increase sensitivity and specificity. Second, we evalu-
ated the cohort selection processes separately, excluding patients with
each of the following: any cancer diagnosis except non-melanoma skin
cancer identified using all available data, as prevalent cancer may also
affect outcome (Tables S5 and S6, Appendix S1); no metformin use dur-
ing baseline, as these patients are treated contrary to guidelines
(Table S7, Appendix S1 and Table 3); diagnosis of congestive heart fail-
ure (CHF), as treated contrary to FDA warning issued for thiazolidine-
diones (Tables S8 and S9, Appendix S1); treatment initiation after the
FDA bladder cancer warning, as propensity to initiate pioglitazone was
likely to change (Tables S10 and S11, Appendix S1), as well as patients
in the upper 1% and 2% tails of the PS distribution of each drug group,
as trimming those treated contrary to prediction can reduce unmeas-
ured confounding29 (Tables S12–S15, Appendix S1). Third, we re-
estimated the PS, excluding indicator variables for calendar time of drug
initiation from the model, as time may be an instrumental variable for
pioglitazone treatment rather than a confounder following the bladder
cancer warning (Tables S16 and S17, Appendix S1).30 Fourth, we imple-
mented a range of grace periods for defining treatment discontinuation
in the AT analysis from 90 to 45 and 180 days (Table S18, Appendix
S1), and we calculated individual grace periods based on the days-sup-
ply, double-days-supply and triple-days-supply of the last dispensing
(Table S19, Appendix S1). Finally, given the poor sensitivity of claims for
identification of smoking status,31 we conducted an external validation
study using data from the 2007 to 2011 Medicare Current Beneficiary
Survey (MCBS). We identified new users of all 3 drug classes based on
Part D data and present data on smoking and BMI reported during the
interview32 (Table S20, Appendix S1).
All data were analyed using SAS, v9.4. The University of North
Carolina at Chapel Hill institutional review board approved this study,
which began as a methodological comparison of various study design
approaches to a comparison of pioglitazone and DPP-4s. Upon
review of the early findings, which suggested a safety concern, a new
study protocol was written and registered in the European Network
of Centres for Pharmacoepidemiology and Pharmacovigilance elec-
tronic register of studies (http://www.encepp.eu, EU PAS Register
Number: EUPAS13279).
3 | RESULTS
Distribution of patient characteristics for those initiating treatment
with pioglitazone vs DPP-4s (38 700 vs 82 552) and those initiating
treatment with pioglitazone vs sulfonylureas (20 075 vs 126 104) is
presented in Table 1. Overall, when compared to each respective
comparator, those who initiated pioglitazone treatment were more
likely to be younger, non-white men, and were less likely to have a
smoking-related claim or to have comorbid diagnoses of cancer,
chronic obstructive pulmonary disorder (COPD) or CHF. Although dif-
ferences were present for both comparisons, they were generally
more pronounced in the sulfonylureas comparison. Relative to DPP-
4s, pioglitazone users were less likely to have a history of use of met-
formin, insulin or angiotensin receptor blocker, which was reversed
when compared to sulfonylureas. After SMR weighting, distribution
of the variables presented in Table 1 for the weighted DPP-4s and
sulfonylureas pseudo-populations became virtually identical to the
pioglitazone group within each respective comparison, indicating no
confounding by these variables.
Table 2 shows incidence rates of bladder cancer per 100 000
person-years (representing post-initiation years for the IT and treat-
ment years for the AT analyses) and corresponding HRs (crude and
fully adjusted) for initiators of pioglitazone vs DPP-4s or sulfonylur-
eas. Median treatment duration (1.1-1.2 years) was similar in all AT
analyses, explained by the frequent treatment changes among






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analyses was >1 year longer for pioglitazone than for DPP-4s or sul-
fonylureas because more patients initiated with pioglitazone in the
earlier years and with DPP-4s in later years.
Compared to DPP-4s initiators in the AT and IT analyses, piogli-
tazone initiators had an increased incidence of bladder cancer overall
(307.8 vs 204.4 per 100 000 person-years; aHR,1.57 [1.23-2.00] and
244.4 vs 195.7; aHR,1.22 [1.02-1.47], respectively). The increased
risk emerged within the first 2 years of treatment (aHR, 1.63 [1.22-
2.17] and 1.38 [1.08-1.77]) and remained after 2 years (aHR, 1.45
[0.93-2.26] and 1.08 [0.82-1.41]). If treatment was discontinued
within the first 2 years, the risk 2 years post-initiation was attenu-
ated (205.3 vs 200.7; aHR, 0.89 [0.61-1.28]).
Compared to sulfonylureas initiators, pioglitazone initiators had
an increased incidence of bladder cancer overall in the AT analysis
(306.3 vs 230.5; aHR, 1.32 [1.02-1.70]), but not in the IT analysis
(223.5 vs 226.6; aHR, 1.02 [0.84-1.24]). However, this is probably an
artifact of longer follow-up available for pioglitazone initiators, as
there was some increased risk when follow-up was restricted to
2 years (241.5 vs 232.9; aHR, 1.05 [0.80-1.36]). If treatment was dis-
continued within the first 2 years, the risk after 2 years post-initiation
was attenuated (179.7 vs 240.0; aHR, 0.82 [0.55-1.23]).
HRs that adjusted for age, sex and race were similar to crude HRs
(Table S2, Appendix S1). Figure 1 displays Kaplan–Meier curves esti-
mated using Cox proportional hazards models, PS-weighted (standar-
dized to the pioglitazone population) for all variables in Table 1, unless
otherwise specified. We identified increasing relative rates of bladder
cancer over time associated with pioglitazone for all analyses, except
the comparison to sulfonylureas in the IT analysis.
Table S1 and Appendix S1 report the AT results from Table 2
with varied induction and latency periods. When no induction or
latency periods were used, aHRs were attenuated for pioglitazone
compared to DPP-4s (1.14 [0.90-1.46]) or sulfonylureas (1.13 [0.87-
1.46]). For both comparisons, similar results were found when induc-
tion was lengthened from 6 to 12 and 18 months. When latency was
shortened from 6 to 3 months, aHRs were attenuated for pioglitazone
vs DPP-4.
Figure 2, which illustrates the relative rates of detection proce-
dures estimated using Cox proportional hazards models, PS-weighted
(standardized to pioglitazone population) for all variables in Table 1,
indicates no appreciable differences for 0 to 6 or >6 to 12 months
post-initiation. In our external validation study using MCBS data
(Table S20), pioglitazone initiators were less likely to have ever been
smokers compared to DPP-4 initiators (48.6% vs 56.2%) and sulfony-
lurea initiators (49.1% vs 60.0%). Pioglitazone initiators were less
likely to be obese (BMI ≥ 30 kg/m2) than were DPP-4 initiators
(38.1% vs 54.3%) and sulfonylurea initiators (42.1% vs 42.8%).
Multiple sensitivity analyses identified more pronounced HRs in
the AT analyses for pioglitazone compared to DPP-4, and attenu-
ated HRs compared to sulfonylureas. These included use of a more
stringent outcome definition (Table S4, Appendix S1) and the sensi-
tive cohorts that excluded patients with the following: prevalent
cancer, CHF, treatment contrary to PS in the 1% and 2% tails, and
no concurrent metformin use (Table S6, S9, S13, and S15, Appendix
S1 and Table 3). Otherwise, sensitivity analyses yielded similar HRs
(Tables S3-S19, Appendix S1).
4 | DISCUSSION
In this incident-user, active-comparator study of a national sample of
older US adults, we identified a risk of bladder cancer associated with
pioglitazone that increased with treatment duration compared to
DPP-4s and sulfonylureas, clinical alternatives for the management of
type-2 diabetes, which was consistent across a wide range of sensi-
tivity analyses.
Weighted Kaplan–Meier curves revealed an increasing rate of
bladder cancer over time, which aligns with results reported for
follow-up <1.5, 1.5 to 4 and >4 years by Lewis et al. (aHR, 0.88 [0.68-
1.16], 1.03 [0.80-1.33], and 1.16 [0.87, 1.54], respectively),4 and with
results reported for follow-up ≤1, 1 to 2 and >2 years by Azoulay
et al. (RR, 0.56 [0.07-4.42), 3.03 [0.63-14.52), and 1.99 [1.14-3.45],
respectively),18 by Tuccori et al. (aHR, 1.33 [0.73-2.40], 1.66 [0.97-
2.84], and 1.78 [1.21-2.64], respectively)16 and by Mackenzie
et al. who evaluated both incident-user (aHR, 1.02 [0.81-1.28], 0.95
[0.62-1.44], and 1.24 [0.83-1.84]) and prevalent-user cohorts (aHR,
1.03 [0.93-1.14], 1.14 [0.98-1.31], and 1.16 [1.00-1.35], respec-
tively).14 Our overall results contradict those that revealed no evi-
dence of increased risk, for multiple reasons including differences in
data source, comparator choice, whether or not prevalent users were
included, and definition of the risk window.
Data sources and inclusion criteria can create potential sources
of selection bias. Three large observational studies assessed the asso-
ciation between pioglitazone and bladder cancer using US data.4,9,14
Lewis et al. who followed Kaiser Permanente Northern California dia-
betes registrants aged 40 years or older,4 and Vallarino et al. who fol-
lowed United Healthcare beneficiaries aged 45 years or older,9 used
cohorts of employer-based commercially insured individuals, which
may under-represent patients at greatest risk of bladder cancer, given
that the median age at diagnosis is 73 years.25 Mackenzie et al. used
a cohort of Medicare beneficiaries similar to ours, but found no evi-
dence of increased risk of bladder cancer for users of pioglitazone
when compared to all other diabetic therapies.14
Our study is the first to compare pioglitazone to DPP-4s, a class
of drugs prescribed to patients similar to those using pioglitazone, as
demonstrated by the balance of measured covariates prior to adjust-
ment and consistency across crude and adjusted HRs for pioglitazone
vs DPP-4s. Sulfonylureas were chosen as an additional comparator,
being the most common therapy after metformin during the study
period.33 A composite comparison of DPP-4s or sulfonylureas was
considered but not included because combining therapies would mix
effects. Comparator choice can strongly influence results, because
treatment choices are routinely based on the underlying disease and
its severity; confounding by severity threatens study validity when
there are major differences in disease severity between those receiv-
ing the study drug and the comparator.20,21 Vallarino et al. found a
reduction in risk of bladder cancer with pioglitazone when compared
to insulin,9 which may be a poor comparator choice as insulin differed
from pioglitazone during much of the study period in three ways:
route of administration (injection vs oral); cost (generally less expen-
sive); and indication (typically indicated for patients with more severe
diabetes). Other studies included all non-pioglitazone antidiabetic
users as the comparator,7,10,13–16,18,33,34 combining therapies for
patients with varying degrees of diabetes severity into 1 group,
TABLE 2 Bladder cancer incidence among initiators of pioglitazone, dipeptidyl-peptidase-4 or sulfonylureas
Comparison Drug
Follow-up (Years),











PIO vs DPP PIO 1.15 (0.67-2.16) 29 651 147 47 766 307.8 1.50 (1.21-1.86) 1.57 (1.23-2.00)
DPP 1.11 (0.59-2.12) 61 438 193 94 426 204.4 1 (reference) 1 (reference)
PIO vs SU PIO 1.11 (0.65-2.09) 15 198 73 23 830 306.3 1.32 (1.02-1.69) 1.32 (1.02-1.70)
SU 1.24 (0.62-2.45) 97 056 387 167 879 230.5 1 (reference) 1 (reference)
Duration of treatment restricted to 2 years
PIO vs DPP PIO 1.15 (0.67-1.97) 29 651 108 36 010 299.9 1.49 (1.16-1.92) 1.63 (1.22-2.17)
DPP 1.11 (0.59-1.97) 61 438 144 71 869 200.4 1 (reference) 1 (reference)
PIO vs SU PIO 1.11 (0.65-1.97) 15 198 57 18 125 314.5 1.30 (0.98-1.73) 1.32 (0.98-1.78)
SU 1.24 (0.62-1.97) 97 056 287 119 458 240.3 1 (reference) 1 (reference)
Duration of treatment after 2 years
PIO vs DPP PIO 1.14 (0.47-2.08) 8367 39 11 756 331.7 1.53 (1.00-2.32) 1.45 (0.93-2.26)
DPP 1.01 (0.41-1.97) 16 894 49 22 557 217.2 1 (reference) 1 (reference)
PIO vs SU PIO 1.11 (0.46-2.07) 4110 16 5706 280.4 1.37 (0.81-2.32) 1.29 (0.76-2.18)
SU 1.23 (0.51-2.29) 31 940 100 48 422 206.5 1 (reference) 1 (reference)
Initial treatment analyses
Overall
PIO vs DPP PIO 3.35 (1.52-4.86) 35 512 282 115 379 244.4 1.26 (1.07-1.49) 1.22 (1.02-1.47)
DPP 1.86 (0.82-3.28) 70 628 308 157 386 195.7 1 (reference) 1 (reference)
PIO vs SU PIO 3.23 (1.39-4.75) 18 224 128 57 282 223.5 0.99 (0.82-1.20) 1.02 (0.84-1.24)
SU 2.05 (0.86-3.73) 108 593 594 262 177 226.6 1 (reference) 1 (reference)
Time since treatment initiation restricted to 2 years
PIO vs DPP PIO 1.97 (1.52-1.97) 35 512 152 58 351 260.5 1.35 (1.09-1.66) 1.38 (1.08-1.77)
DPP 1.86 (0.82-1.97) 70 628 194 99 661 194.7 1 (reference) 1 (reference)
PIO vs SU PIO 1.97 (1.39-1.97) 18 224 71 29 399 241.5 1.04 (0.81-1.34) 1.05 (0.80-1.36)
SU 1.97 (0.86-1.97) 108 593 364 156 316 232.9 1 (reference) 1 (reference)
Time since treatment initiation after 2 years
PIO vs DPP PIO 2.28 (1.28-3.36) 24 488 130 57 028 228.0 1.16 (0.90-1.49) 1.08 (0.82–1.41)
DPP 1.38 (0.61-2.64) 33 748 114 57 725 197.5 1 (reference) 1 (reference)
PIO vs SU PIO 2.22 (1.25-3.33) 12 187 57 27 883 204.4 0.93 (0.70-1.24) 0.99 (0.73-1.32)
SU 1.69 (0.76-2.92) 55 848 230 105 861 217.3 1 (reference) 1 (reference)
Initial treatment analyses -
restricted to patients
with ≤ 2-year duration of
treatment
Time since treatment initiation after 2 years
PIO vs DPP PIO 2.15 (1.22-3.24) 16 121 74 36 042 205.3 1.02 (0.72-1.44) 0.89 (0.61-1.28)
DPP 1.35 (0.57-2.62) 16 854 57 28 404 200.7 1 (reference) 1 (reference)
PIO vs SU PIO 2.10 (1.20-3.21) 8077 32 17 807 179.7 0.74 (0.50-1.10) 0.82 (0.55-1.23)
SU 1.60 (0.70-2.83) 23 908 105 43 745 240.0 1 (reference) 1 (reference)
Abbrevaitions: CI, Confidence Interval; DPP, dipeptidyl-peptidase-4; HR, hazard ratio; IQR, interquartile range; PIO, pioglitazone; SU, sulfonylureas.
a Follow-up began on the cohort entry date (second dispensing) and was censored at first occurrence of outcome, death, end of study (December 2014)
or end of enrollment. As-treated analyses were additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period). A 180-day induction period was imposed, excluding time from the beginning of follow-up. As-treated analyses addi-
tionally added a 180-day latency period to the end of follow-up, when possible, prior to death or end of patient data.
b Number contributing with at least 180 days of follow-up. Those who initiated PIO differs for each comparison because of exclusions of prior use of
drugs included in comparison only.
c Incidence rate reported per 100 000 person-years.
d Cox proportional hazards models.
e Cox proportional hazards models adjusted for all variables in Table 1, except for those excluded within each comparison by incident user design, using
propensity-score weighting (standardized to PIO population).
making it difficult to determine individual treatment effects and
increasing the potential for biased estimates.
An active comparator is recommended for comparative effective-
ness research, to present the least biased estimates.20,21 Including
untreated patients with diabetes in the comparator4,13 can threaten
validity further as a result of confounding by indication, as these
patients may be able to manage their diabetes without medical ther-
apy (eg, diet and exercise). Using claims, we were unable to fully con-
trol for 2 known risk factors for bladder cancer, smoking and
workplace exposures (ie, industrial chemicals).25 A smoking algorithm
with excellent specificity but poor sensitivity (27.9%)31 was added, to
identify smoking-related claims. Diagnosis of COPD was also included
in the PS model as a smoking status proxy. In our external validation
study, pioglitazone initiators were less likely to be smokers and to
be obese than were comparator drug initiators. Assuming transporta-
bility of MCBS to our sample, the increased risk of bladder cancer
observed cannot be explained by residual confounding by smoking or
BMI, and may actually be an underestimation of the true risk.
Our study has other limitations that should be considered when
interpreting results. Bladder cancer was defined using administrative
claims without pathological confirmation; thus, misclassification is possi-
ble, but unlikely to be differential with respect to treatment choice. We
used a previously validated algorithm for identifying solid tumours in
administrative claims24 and varied the definition in sensitivity analyses
to confirm similar results. Timing of outcome ascertainment is especially
important for cancer outcomes, given the unlikelihood that short-term
treatment will have an immediate causal impact. For example, subse-
quent review of the 11 bladder neoplasms (8 pioglitazone and 3 placebo)
reported within the first year of the PROactive study3 allowed us to
conclude that the events could not have been caused by short-term
exposure.12 As the actual risk period relevant for drug-associated can-
cers is poorly understood, evaluating multiple risk windows, as we did,
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FIGURE 1 Weighted Kaplan–Meier
curves identifying participants
remaining without bladder cancer
throughout follow-up among initiators
of pioglitazone (dotted gray line) or
active comparator (solid black line;
dipeptidyl-peptidase-4 or
sulfonylureas) with at least 180 days of
follow-up
Months before and after drug initiation














Pioglitazone vs SulfonylureasPioglitazone vs DPP-4
FIGURE 2 Relative rates of bladder
cancer-related diagnostic procedures
6 and 12 months before and after
initiation of pioglitazone, dipeptidyl-
peptidase-4 and sulfonylureas where
circle = cystoscopy, triangle = cytology,
square = non-dipstick urinalysis,
star = dipstick urinalysis,
diamond = urine function test
minimizes the potential for protopathic bias or the identification of spu-
rious events following misclassification of the risk period.35,36 Further-
more, using both IT and AT approaches allowed us to present
conservative estimates via the IT approach, in addition to treatment-
duration-specific estimates via the AT approach.
Detection bias was another potential concern for this study.
Annual urinalysis is recommended for patients with diabetes, given
the increased risk of kidney disease.37,38 Edema, a common side-
effect of pioglitazone,39 may lead to additional urological screening
and diagnostic work-up, because it can also be an early sign of kidney
disease.40 Our additional analyses did not reveal evidence of an
increased rate of these procedures in pioglitazone initiators compared
to DPP-4s or sulfonylureas initiators, which eliminated detection bias
as an explanation for our findings.
In summary, we identified an increased risk of bladder cancer
associated with pioglitazone treatment, as suggested by some,15–18













PIO vs DPP PIO 1.17 (0.67-2.21) 14 476 75 23 713 316.3 1.75 (1.29-2.38) 1.82 (1.28-2.59)
DPP 1.14 (0.60-2.17) 32 088 91 50 400 180.6 1 (reference) 1 (reference)
PIO vs SU PIO 1.17 (0.67-2.17) 6819 27 11 059 244.1 1.18 (0.78-1.77) 1.21 (0.79-1.85)
SU 1.31 (0.65-2.58) 43 281 161 77 736 207.1 1 (reference) 1 (reference)
Duration of treatment restricted to 2 years
PIO vs DPP PIO 1.17 (0.67-1.97) 14 476 53 17 768 298.3 1.69 (1.18-2.43) 1.80 (1.17-2.76)
DPP 1.14 (0.60-1.97) 32 088 67 38 016 176.2 1 (reference) 1 (reference)
PIO vs SU PIO 1.17 (0.67-1.97) 6819 18 8315 216.5 1.02 (0.62-1.68) 1.03 (0.62-1.73)
SU 1.31 (0.65-1.97) 43 281 115 54 678 210.3 1 (reference) 1 (reference)
Duration of treatment after 2 years
PIO vs DPP PIO 1.13 (0.47-2.09) 4214 22 5945 370.0 1.91 (1.07-3.41) 1.86 (1.02-3.41)
DPP 1.03 (0.43-2.00) 9129 24 12 384 193.8 1 (reference) 1 (reference)
PIO vs SU PIO 1.13 (0.47-2.12) 1942 <11 NR 328.0 1.65 (0.81-3.38) 1.65 (0.81-3.37)
SU 1.24 (0.51-2.31) 15 159 46 23 058 199.5 1 (reference) 1 (reference)
Initial-treatment analyses
Overall
PIO vs DPP PIO 3.41 (1.57-4.86) 17 081 133 56 079 237.2 1.40 (1.10-1.79) 1.31 (1.00-1.72)
DPP 1.90 (0.84-3.31) 36 450 140 81 932 170.9 1 (reference) 1 (reference)
PIO vs SU PIO 3.32 (1.46-4.80) 8022 51 25 684 198.6 1.07 (0.79-1.45) 1.11 (0.81-1.52)
SU 2.12 (0.91-3.81) 47 590 219 117 202 186.9 1 (reference) 1 (reference)
Time since treatment initiation restricted to 2 years
PIO vs DPP PIO 1.97 (1.57-1.97) 17 081 71 28 215 251.6 1.43 (1.05-1.96) 1.38 (0.96-1.99)
DPP 1.90 (0.84-1.97) 36 450 91 51 710 176.0 1 (reference) 1 (reference)
PIO vs SU PIO 1.97 (1.46-1.97) 8022 23 13 063 176.1 0.87 (0.56-1.36) 0.88 (0.56-1.38)
SU 1.97 (0.91-1.97) 47 590 141 69 406 203.2 1 (reference) 1 (reference)
Time since treatment initiation after 2 years
PIO vs DPP PIO 2.27 (1.29-3.32) 11 993 62 27 865 222.5 1.37 (0.93-2.00) 1.24 (0.84-1.84)
DPP 1.39 (0.62-2.65) 17 644 49 30 222 162.1 1 (reference) 1 (reference)
PIO vs SU PIO 2.21 (1.27-3.29) 5506 28 12 621 221.9 1.34 (0.87-2.06) 1.43 (0.92-2.23)
SU 1.71 (0.77-2.93) 25 124 78 47 796 163.2 1 (reference) 1 (reference)
Abbreviations: CI, confidence interval; DPP, dipeptidyl-peptidase-4; HR, hazard ratio; IQR, interquartile range; NR, not reportable given number of events
<11; PIO, pioglitazone; SU, sulfonylureas.
a Follow-up began on the cohort entry date (second dispensing) and was censored at first occurrence of outcome, death, end of study (December 2014)
or end of enrollment. As-treated analyses were additionally censored at treatment discontinuation (no subsequent fill of initiated drug class within days-
supply plus a 90-day grace period). A 180-day induction period was imposed, excluding time from the beginning of follow-up. As-treated analyses addi-
tionally added a 180-day latency period to the end of follow-up, when possible, prior to death or end of patient data.
b Number contributing with at least 180 days of follow-up. The number initiating PIO differs for each comparison because of exclusions of prior use of
drugs included in comparison only.
c Incidence rate reported per 100 000 Person-years.
d Cox proportional hazards models.
e Cox proportional hazards models adjusted for all variables in Table 1, except for metformin and those excluded within each comparison by incident user
design, using propensity-score weighting (standardized to PIO population).
but disputed by others.4,7–14 The risk emerged within the first 2 years
of treatment and increased over time. Findings from our secondary
and sensitivity analyses suggest that these results are unlikely to be
explained by differential detection rates, cohort selection, outcome
definitions or censoring approaches. It is important to note that rela-
tive differences reflected when reporting hazard ratios may distort
clinical interpretation, as the crude absolute risk differences were
incredibly small, requiring over 1000 person-years of treatment to
observe one excess bladder cancer event for pioglitazone compared
to DPP-4s or sulfonylureas. Therefore, when considering which diabe-
tic treatment to prescribe, pioglitazone’s tolerability and effectiveness
in maintaining blood-glucose control relative to clinical alternatives41
should be weighed against a small absolute increase in risk of bladder
cancer. Although rare, bladder cancer is the fifth most common cancer,
representing 4.6% of all new cancer cases in the USA.25 With the con-
tinued development and marketing of new antidiabetic medications,
evaluation of their safety, using study design and analytic methods
that minimize all threats to validity, is increasingly important.
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